Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

PRE-Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis: A Phase I/Ib Platform Trial

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05868226
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:26:38.687069+00:00
Published At
2025-04-04T00:00:00+00:00
Record Updated At
2025-04-04
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["HER2-positive Breast Cancer", "Metastatic Cancer", "Metastatic Breast Cancer", "Metastatic", "HER2-positive Metastatic Breast Cancer", "HER2 Mutation-Related Tumors", "HER-2 Protein Overexpression", "HER2-negative Breast Cancer", "Triple Negative Breast Cancer", "HR Positive", "Hormone Receptor-positive Breast Cancer", "Estrogen Receptor Positive Tumor", "Progesterone Receptor-positive Breast Cancer", "Hormone Receptor Negative Breast Carcinoma", "Solid Tumor", "Solid Tumor, Adult", "Solid Carcinoma", "HER2 Low Breast Cancer", "HER2 Low Breast Carcinoma", "ER Positive Breast Cancer", "PR-positive Breast Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-04-04"
protocolSection.identificationModule.nctId
"NCT05868226"
protocolSection.identificationModule.officialTitle
"PRE-Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis: A Phase I/Ib Platform Trial"
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • HER2-positive Breast Cancer (protocolSection.conditionsModule.conditions)
  • Metastatic Cancer (protocolSection.conditionsModule.conditions)
  • Metastatic Breast Cancer (protocolSection.conditionsModule.conditions)
  • Metastatic (protocolSection.conditionsModule.conditions)
  • HER2-positive Metastatic Breast Cancer (protocolSection.conditionsModule.conditions)
  • HER2 Mutation-Related Tumors (protocolSection.conditionsModule.conditions)
  • HER-2 Protein Overexpression (protocolSection.conditionsModule.conditions)
  • HER2-negative Breast Cancer (protocolSection.conditionsModule.conditions)
  • Triple Negative Breast Cancer (protocolSection.conditionsModule.conditions)
  • HR Positive (protocolSection.conditionsModule.conditions)
  • Hormone Receptor-positive Breast Cancer (protocolSection.conditionsModule.conditions)
  • Estrogen Receptor Positive Tumor (protocolSection.conditionsModule.conditions)
  • Progesterone Receptor-positive Breast Cancer (protocolSection.conditionsModule.conditions)
  • Hormone Receptor Negative Breast Carcinoma (protocolSection.conditionsModule.conditions)
  • Solid Tumor (protocolSection.conditionsModule.conditions)
  • Solid Tumor, Adult (protocolSection.conditionsModule.conditions)
  • Solid Carcinoma (protocolSection.conditionsModule.conditions)
  • HER2 Low Breast Cancer (protocolSection.conditionsModule.conditions)
  • HER2 Low Breast Carcinoma (protocolSection.conditionsModule.conditions)
  • ER Positive Breast Cancer (protocolSection.conditionsModule.conditions)
  • PR-positive Breast Cancer (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.